Editorial
England will introduce a new aligned review pathway between the Medicines and Healthcare products Regulatory Agency and National Institute for Health and Care Excellence from 1 April, allowing regulatory approval and cost-effectiveness evaluation to run in parallel and potentially enabling patients to access new medicines up to six months earlier.
Patients in England could gain access to new medicines up to six months earlier under a streamlined regulatory and evaluation pathway being introduced jointly by the Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE). The new aligned process will officially launch on 1 April, allowing regulatory approval and health technology assessment to run in parallel.
Traditionally, medicines receive regulatory authorization from the MHRA before NICE begins evaluating their clinical and cost-effectiveness for use within the NHS. Under the new pathway, both agencies will conduct their assessments simultaneously. This alignment is expected to accelerate final decisions on licensing and reimbursement, enabling patients in England to receive innovative treatments three to six months earlier.
Beyond improving patient access timelines, the initiative also addresses a long-standing challenge in the UK medicines approval system. Historically, medicines underwent a sequential process in which MHRA authorization was followed by a separate cost-effectiveness evaluation by NICE, potentially delaying availability within the NHS. By aligning both reviews, the new pathway aims to reduce this gap and strengthen the UK’s position as an early launch market for innovative medicines.
The initiative forms part of commitments outlined in the UK government’s 10 Year Health Plan for England and the Life Sciences Sector Plan, which emphasize closer collaboration between regulators and health technology assessment bodies to accelerate patient access to medicines while maintaining safety and value standards.
Alongside the aligned pathway, MHRA and NICE are introducing an enhanced Integrated Scientific Advice service designed to support pharmaceutical companies earlier in drug development. The service will provide a single-entry point for companies seeking joint advice from both organizations, including one coordinated meeting, a unified report, and a single fee. By aligning expectations around clinical data and evidence requirements, the program aims to help developers design stronger clinical development strategies and reduce delays later in the approval process.
The new services were announced during the NICE Conference in Manchester by NICE Chief Executive Jonathan Benger and MHRA Chief Executive Lawrence Tallon. Both agencies highlighted that closer collaboration will help ensure faster access to innovative medicines while strengthening the UK’s attractiveness as a launch market for global life sciences companies.
According to the agencies, pharmaceutical companies were invited in October 2025 to participate as early adopters of the aligned pathway. A total of 27 companies have already joined the program, and the first medicines are currently undergoing review under the new framework. Initial NICE guidance decisions from this process are expected by June 2026.
The reform also reflects broader efforts by the UK government to enhance the country’s attractiveness for life sciences investment. Drug developers often prioritize markets where regulatory approval and reimbursement decisions occur rapidly. By synchronizing MHRA licensing reviews with NICE value assessments, the UK aims to shorten the timeline between approval and NHS availability and encourage companies to launch new medicines earlier in the country.
UK Health Innovation and Safety Minister Zubir Ahmed said the initiative aims to cut regulatory delays while maintaining strong safety standards, allowing NHS patients to access safe and effective treatments sooner while supporting investment in the country’s life sciences sector.
Reference
Patients to get new medicines up to six months sooner under new joint MHRA-NICE approval process, 17 March 2026, https://www.gov.uk/government/news/patients-to-get-new-medicines-up-to-six-months-sooner-under-new-joint-mhra-nice-approval-process
Patients to get new medicines 3 to 6 months faster, 17 March 2026, https://www.nice.org.uk/news/articles/patients-to-get-new-medicines-up-to-six-months-sooner-under-new-joint-mhra-nice-approval-process